Nanodrug-based therapeutic interventions for tumor-associated microbiota modulation.

Area of Science:

• Oncology
• Microbiome Research
• Nanotechnology

Background:

• The tumor microenvironment (TME) is a complex ecosystem influencing cancer progression and treatment.
• Tumor-associated microbiota within the TME play a critical role in metastasis, immune evasion, and therapeutic resistance.

Purpose of the Study:

• To review the role of tumor-associated microbiota in cancer biology.
• To explore mechanisms by which microbiota affect tumor progression and treatment resistance.
• To highlight nanodrug-based strategies for microbiome modulation in cancer therapy.

Main Methods:

• Analysis of high-throughput sequencing data to characterize tumor-associated microbial communities.
• Review of existing literature on microbe-tumor cell and microbe-immune system interactions.
• Exploration of nanotechnology-based platforms for targeted microbiome modulation.

Main Results:

• Distinct microbial communities are associated with various tumor types, influencing inflammation and immune responses.
• Microbiota can promote tumor metastasis and immune evasion, contributing to treatment resistance.
• Nanotechnology offers potential for precise microbiome targeting and combination therapy delivery within the TME.

Conclusions:

• Tumor-associated microbiota significantly impact cancer development and therapeutic outcomes.
• Targeting the microbiome with nanodrugs presents a promising strategy for enhancing cancer treatment efficacy.
• Further research is needed to overcome challenges posed by microbiome and TME heterogeneity for universal application.